Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 8/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925557 | 0.90 | CCR3 (0.60) | CCR3MCHR1 | |
| SCHEMBL18844433 | 0.77 | CCR3 (1.00) | CCR3MCHR1SLC6A12TMEM97SIGMAR1 | |
| SCHEMBL23655984 | 0.75 | PRKAA2 (0.56) | CCR3MCHR1SLC6A12TMEM97SIGMAR1 | |
| SCHEMBL18841090 | 0.73 | CCR3 (1.00) | CCR3MCHR1 | |
| SCHEMBL9792346 | 0.70 | MCHR1 (0.84) | CCR3MCHR1SLC6A12TMEM97SIGMAR1 | |
| SCHEMBL13177223 | 0.69 | MCHR1 (0.59) | CCR3MCHR1 | |
| SCHEMBL4031883 | 0.68 | MEN1 (0.79) | CCR3MCHR1SLC6A12TMEM97SIGMAR1 | |
| SCHEMBL2926876 | 0.67 | MCHR1 (0.56) | MCHR1 | |
| SCHEMBL4749226 | 0.67 | NPC1 (0.67) | CCR3MCHR1SLC6A12TMEM97SIGMAR1 | |
| SCHEMBL17078480 | 0.67 | HDAC6 (0.55) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | CCR3 1149/4885MCHR1 1/4885OPRK1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.